Hospital

The study also found that 82% of the surveyed physicians reported not getting labs to help determine treatment options for their patients.

The products include Crovalimab, Dapagliflozin, Secukinumab, Roflumilast

Taurolidine and heparin (Defencath; CorMedix) is indicated to reduce catheter-related bloodstream infections for adults with kidney failure who are receiving chronic hemodialysis via central venous catheter

Session speaker Powell-Wiley explains how screening for SDOH in patients as cardiovascular-kidney-metabolic syndrome stages progress can help better understand their individual social needs.

In this episode, you'll hear a conversation with Ron Lanton, partner at Lanton Law, who gets us up to speed on all of the legal cases surrounding this issue thus far.

According to the authors, these results contribute to developing information that associate lymphedema with localized changes in immunity and a susceptibility for cancer.

Compared to the standard prenatal vitamin alone, vitamin D supplementation with the prenatal vitamin reduced the risk of asthma and wheezing in children by approximately 50%.

Ince describes why patients who are considered fragile are often underdiagnosed and undertreated, and that the VOYAGER PAD analyses can encourage the treatment of the fragile population.

Even with the current available treatment options, it is important to recognize the importance of masking, particularly for those with immunocompromised conditions.

Safe handling of hazardous drugs plays a vital role in patient care.

Bonaca also notes that pharmacists can play a key role in educating patients and clinicians about the appropriate use and dosing of antithrombotic drugs for vascular protection.

Harrington discusses how the performance of milvexian in prior phase 2 trials focused on different patient populations creates the foundation for future research.

Sehnert emphasizes that mavacamten treatment benefits were present in both patients with sarcomere mutation positive HCM and sarcomere mutation negative HCM.

Bupivacaine liposome injectable suspension was shown to reduce opioid use after surgery and significantly improve pain.

Throat indications contribute to high antibiotic overprescribing rates.

The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.

The vaccine provides treatment prevention for individuals that are high risk of exposure to the chikungunya virus.

The on-demand enzyme replacement therapy reduced acute thrombotic thrombocytopenic purpura events in patients who experience potentially fatal blood clotting.

The study findings provide the first in-depth look at the relationship between chromosomal changes in tumor cells and immune components of the tumor microenvironment.

Health policies to adapt to climate change must be altered to protect individuals with respiratory diseases in the warmer season.

Twenty states proposed bills to prohibit white bagging and brown bagging policies this year.

Researchers determined that simultaneously targeting the BRD4 and LOXL2 proteins disrupts their interaction and inhibits the growth of triple-negative breast cancer cells.

Women with inflammation during COVID-19 infection are at higher risk for Long Covid symptoms, according to study results.

With this approval, fruquintinib is the first and only selective inhibitor of all 3 VEGR receptor kinases to be approved in the United States for previously treated mCRC, regardless of biomarker status.

Socioeconomic, racial, and insurance disparities impact individuals' health before and after receiving surgery to treat adolescent idiopathic scoliosis.

Pharmacists are accessible and trusted health care professionals who have an important role in supporting people living with mental illness.

Domvanalimab plus zimberelimab with chemotherapy demonstrated a positive overall response rate and 6-month progression free survival rate for patients with upper gastrointestinal cancers.

More individuals with systemic lupus erythematosus treated with anifrolumab-fnia reached remission compared to the placebo.